RBC Capital Maintains Sector Perform on CRISPR Therapeutics, Lowers Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi maintains a Sector Perform rating on CRISPR Therapeutics but lowers the price target from $60 to $53.
October 04, 2024 | 3:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RBC Capital has maintained its Sector Perform rating on CRISPR Therapeutics but has lowered the price target from $60 to $53, indicating a less optimistic outlook.
The lowering of the price target by RBC Capital suggests a less optimistic view on CRISPR Therapeutics' future performance, which could negatively impact the stock price in the short term. The maintained Sector Perform rating indicates a neutral stance, but the reduced price target is a bearish signal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100